Viking's obesity drug proves to be beneficial in clinical trials

Time : 30th of March 2023 12:28:35 PM

The injectable drug developed by Viking Therapeutics helped obese patients lose almost 8% of their body weight in a small phase 1 clinical trial. The 10 mg per week dose of the drug caused the largest weight loss. Viking's drug, VK2735, activates two insulin-stimulating hormones, which Eli Lily's drug also activates. Eli Lily's drug Mounjaro is in phase 3 trials now.



obesity drug, injectable, Viking Therapeutics

Recent Posts

FDA warns against compounding semaglutide
2nd of June 2023 04:00:38 PM

Alzheimer's could raise the risk of epilepsy
2nd of June 2023 03:35:09 PM

Exercise could improve pain tolerance
2nd of June 2023 02:43:04 PM

New treatment for REM sleep behaviour disorder
31st of May 2023 01:00:19 PM